TMEM37 and myelodysplastic syndrome: Similar to the WT-1 vaccine, the PR-1 vaccine has been found to be safe, effective and displays a potential therapeutic role in settings of low tumor burden including low-risk MDS, or as consolidation therapy in higher-risk MDS [36].